Certuity’s Neurocrine Biosciences NBIX Stock Holding History

Certuity’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,150	Closed	-$415K	–	367
2023 Q4	$415K	Buy	+3,150	New	+$363K	0.04%	204
2021 Q2	–	Sell	-2,310	Closed	-$225K	–	365
2021 Q1	$225K	Buy	+2,310	New	+$242K	0.06%	262

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Certuity's NBIX Position: Q1 2024 in Review

Certuity sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 3,150 shares — an estimated $415K sold.

Certuity first reported a position in NBIX in Q1 2021 and held it in 2 quarters. The position peaked at $415K in Q4 2023. 589 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

Certuity reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
Certuity sold 3,150 Neurocrine Biosciences shares in Q1 2024, an estimated $415K.
Certuity first reported a position in Neurocrine Biosciences in Q1 2021 and held it in 2 quarters.
Certuity's Neurocrine Biosciences position peaked at $415K in Q4 2023.
589 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on Certuity's 13F filing for Q1 2024, filed 15 May 2024.